FGF13

Across TCGA pan-cancer cohorts, FGF13 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FGF13 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher FGF13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FGF13 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PAAD and LUAD are the cancer types where FGF13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Median	All	0.098	0.505	.002	24	view →
LUAD	DFS	Median	All	1.000	0.328	.026	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FGF13–PAAD (DFS)

Open the PAAD breakdown →